Auto-populated list of related Clinical Trials
(Breast, Cleft Lip and Palate, Hand, Lymphedema, Oral, Skin, Trauma)

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without ganitumab in treating patients with newly diagnosed Ewing sarcoma.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: Cyclophosphamide
  • Drug: Doxorubicin Hydrochloride
  • Drug: Etoposide
  • Radiation: External Beam Radiation Therapy
  • Biological: Ganitumab
  • Drug: Ifosfamide
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Radiation: Stereotactic Radiosurgery
  • Procedure: Therapeutic Surgical Procedure
  • Drug: Vincristine Sulfate

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed
   Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone
   or soft tissue and with metastatic disease involving lung, bone, bone marrow, or other
   metastatic site

   - For the purpose of this study metastatic disease is defined as one or more of the
   following:

      - Lesions which are discontinuous from the primary tumor, are not regional lymph
      nodes, and do not share a bone or body cavity with the primary tumor; skip
      lesions in the same bone as the primary tumor do not constitute metastatic
      disease; skip lesions in an adjacent bone are considered bone metastases; if
      there is any doubt whether lesions are metastatic, a biopsy of those lesions
      should be performed

      - Contralateral pleural effusion and/or contralateral pleural nodules

      - Distant lymph node involvement

      - Patients with pulmonary nodules are considered to have metastatic disease if the
      patient has:

         - Solitary nodule >= 0.5 cm or multiple nodules of >= 0.3 cm unless lesion is
         biopsied and negative for tumor

         - Patients with solitary nodule < 0.5 cm or multiple nodules < 0.3 cm are not
         considered to have lung metastasis unless biopsy documents tumor

      - Bone marrow metastatic disease is based on morphologic evidence of Ewing sarcoma
      based on hematoxylin and eosin (H&E) stains; in the absence of morphologic
      evidence of marrow involvement on H&E, patients with bone marrow involvement
      detected ONLY by flow cytometry, reverse-transcriptase (RT)-polymerase chain
      reaction (PCR), fluorescence in situ hybridization (FISH), or
      immunohistochemistry will NOT be considered to have clinical bone marrow
      involvement for the purposes of this study

         - This study requires bilateral bone marrow biopsies at study entry; the
         suggested approach for patients with large pelvic tumors in which a
         posterior iliac crest bone marrow biopsy would track through the tumor is to
         instead undergo 2 marrow biopsies on the contralateral side (either 2
         posterior biopsies or one posterior and one anterior biopsy)

      - Bone metastasis: This study utilizes whole body FDG-PET scans to screen patients
      for bone metastases; areas suspicious for bone metastasis based on FDG-PET scans
      require confirmatory anatomic imaging with either MRI or computed tomography (CT)
      (whole body FDG-PET/CT or FDG-PET/magnetic resonance [MR] scan acceptable); whole
      body technetium bone scans may be performed at the discretion of the investigator
      and are not required; for patients without other sites of metastatic disease
      whose sole metastatic site to qualify for study entry is a single area suspicious
      for bone metastasis identified by FDG-PET, confirmatory biopsy or anatomic
      imaging evidence of an associated soft tissue mass at that site is required for
      study entry

   - Patients must have adequate tumor tissue to meet the minimum requirement for
   submission

   - Enrolling institutions are reminded that submission of pre-treatment serum, tumor
   tissue and whole blood is required

   - Patients should only have had a biopsy of the primary tumor without an attempt at
   complete or partial resection; patients will still be eligible if excision was
   attempted or accomplished as long as adequate anatomic imaging (MRI for most primary
   tumor sites) was obtained prior to surgery

   - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
   mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

      - Age < 6 months: Maximum serum creatinine (mg/dL): 0.4 for males and females

      - Age 6 months to < 1 year: Maximum serum creatinine (mg/dL): 0.5 for males and
      females

      - Age 1 to < 2 years: Maximum serum creatinine (mg/dL): 0.6 for males and females

      - Age 2 to < 6 years: Maximum serum creatinine (mg/dL): 0.8 for males and females

      - Age 6 to < 10 years: Maximum serum creatinine (mg/dL): 1 for males and females

      - Age 10 to < 13 years: Maximum serum creatinine (mg/dL): 1.2 for males and females

      - Age 13 to < 16 years: Maximum serum creatinine (mg/dL): 1.5 for males and 1.4 for
      females

      - Age >= 16 years: Maximum serum creatinine (mg/dL): 1.7 for males and 1.4 for
      females

   - Total bilirubin =< 1.5 x upper limit of normal (ULN) for age, and

   - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 3 x
   upper limit of normal (ULN) for age (except for patients with liver metastasis who may
   enroll if ALT < 5 times ULN for age)

   - Shortening fraction of >= 27% or

   - Ejection fraction of >= 50%

   - Patients must have a normal blood sugar level for age to participate; if an initial
   random draw (ie. non-fasting) blood glucose value is out of range, it is acceptable to
   repeat this test as a fasting draw

   - All patients and/or their parents or legal guardians must sign a written informed
   consent

   - All institutional, Food and Drug Administration (FDA), and National Cancer Institute
   (NCI) requirements for human studies must be met

Exclusion Criteria:

   - Patients with regional node involvement as their only site of disease beyond the
   primary tumor will not be eligible

   - Patients whose primary tumors arise in the intra-dural soft tissue (eg. brain and
   spinal cord) are not eligible

   - Patients who have received prior chemotherapy or radiation therapy are not eligible

   - Female patients of childbearing potential are not eligible unless a negative pregnancy
   test result has been obtained; lactating females are not eligible unless they have
   agreed not to breastfeed their infants for the duration of protocol therapy; sexually
   active patients of reproductive potential are not eligible unless they have agreed to
   use an effective contraceptive method for the duration of protocol therapy

   - Patients with known pre-existing diabetes mellitus will be excluded from study

   - Patients receiving chronic pharmacologic doses of corticosteroids are not eligible;
   for the purposes of eligibility, chronic exposure is defined as anticipated exposure
   of > 3 weeks, including the sum of both pre-enrollment and anticipated post-enrollment
   dosing; patients on acute corticosteroid therapy (=< 3 weeks of total planned
   exposure) must still meet the normal blood glucose requirement; patients receiving
   chronic inhaled corticosteroids or chronic physiologic replacement doses of
   corticosteroids are eligible

Ages Eligible for Study

N/A - 50 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christina Baggott
650-497-7659
Recruiting

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without ganitumab in treating patients with newly diagnosed Ewing sarcoma.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: Cyclophosphamide
  • Drug: Doxorubicin Hydrochloride
  • Drug: Etoposide
  • Radiation: External Beam Radiation Therapy
  • Biological: Ganitumab
  • Drug: Ifosfamide
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Radiation: Stereotactic Radiosurgery
  • Procedure: Therapeutic Surgical Procedure
  • Drug: Vincristine Sulfate

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed
   Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone
   or soft tissue and with metastatic disease involving lung, bone, bone marrow, or other
   metastatic site

   - For the purpose of this study metastatic disease is defined as one or more of the
   following:

      - Lesions which are discontinuous from the primary tumor, are not regional lymph
      nodes, and do not share a bone or body cavity with the primary tumor; skip
      lesions in the same bone as the primary tumor do not constitute metastatic
      disease; skip lesions in an adjacent bone are considered bone metastases; if
      there is any doubt whether lesions are metastatic, a biopsy of those lesions
      should be performed

      - Contralateral pleural effusion and/or contralateral pleural nodules

      - Distant lymph node involvement

      - Patients with pulmonary nodules are considered to have metastatic disease if the
      patient has:

         - Solitary nodule >= 0.5 cm or multiple nodules of >= 0.3 cm unless lesion is
         biopsied and negative for tumor

         - Patients with solitary nodule < 0.5 cm or multiple nodules < 0.3 cm are not
         considered to have lung metastasis unless biopsy documents tumor

      - Bone marrow metastatic disease is based on morphologic evidence of Ewing sarcoma
      based on hematoxylin and eosin (H&E) stains; in the absence of morphologic
      evidence of marrow involvement on H&E, patients with bone marrow involvement
      detected ONLY by flow cytometry, reverse-transcriptase (RT)-polymerase chain
      reaction (PCR), fluorescence in situ hybridization (FISH), or
      immunohistochemistry will NOT be considered to have clinical bone marrow
      involvement for the purposes of this study

         - This study requires bilateral bone marrow biopsies at study entry; the
         suggested approach for patients with large pelvic tumors in which a
         posterior iliac crest bone marrow biopsy would track through the tumor is to
         instead undergo 2 marrow biopsies on the contralateral side (either 2
         posterior biopsies or one posterior and one anterior biopsy)

      - Bone metastasis: This study utilizes whole body FDG-PET scans to screen patients
      for bone metastases; areas suspicious for bone metastasis based on FDG-PET scans
      require confirmatory anatomic imaging with either MRI or computed tomography (CT)
      (whole body FDG-PET/CT or FDG-PET/magnetic resonance [MR] scan acceptable); whole
      body technetium bone scans may be performed at the discretion of the investigator
      and are not required; for patients without other sites of metastatic disease
      whose sole metastatic site to qualify for study entry is a single area suspicious
      for bone metastasis identified by FDG-PET, confirmatory biopsy or anatomic
      imaging evidence of an associated soft tissue mass at that site is required for
      study entry

   - Patients must have adequate tumor tissue to meet the minimum requirement for
   submission

   - Enrolling institutions are reminded that submission of pre-treatment serum, tumor
   tissue and whole blood is required

   - Patients should only have had a biopsy of the primary tumor without an attempt at
   complete or partial resection; patients will still be eligible if excision was
   attempted or accomplished as long as adequate anatomic imaging (MRI for most primary
   tumor sites) was obtained prior to surgery

   - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
   mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

      - Age < 6 months: Maximum serum creatinine (mg/dL): 0.4 for males and females

      - Age 6 months to < 1 year: Maximum serum creatinine (mg/dL): 0.5 for males and
      females

      - Age 1 to < 2 years: Maximum serum creatinine (mg/dL): 0.6 for males and females

      - Age 2 to < 6 years: Maximum serum creatinine (mg/dL): 0.8 for males and females

      - Age 6 to < 10 years: Maximum serum creatinine (mg/dL): 1 for males and females

      - Age 10 to < 13 years: Maximum serum creatinine (mg/dL): 1.2 for males and females

      - Age 13 to < 16 years: Maximum serum creatinine (mg/dL): 1.5 for males and 1.4 for
      females

      - Age >= 16 years: Maximum serum creatinine (mg/dL): 1.7 for males and 1.4 for
      females

   - Total bilirubin =< 1.5 x upper limit of normal (ULN) for age, and

   - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 3 x
   upper limit of normal (ULN) for age (except for patients with liver metastasis who may
   enroll if ALT < 5 times ULN for age)

   - Shortening fraction of >= 27% or

   - Ejection fraction of >= 50%

   - Patients must have a normal blood sugar level for age to participate; if an initial
   random draw (ie. non-fasting) blood glucose value is out of range, it is acceptable to
   repeat this test as a fasting draw

   - All patients and/or their parents or legal guardians must sign a written informed
   consent

   - All institutional, Food and Drug Administration (FDA), and National Cancer Institute
   (NCI) requirements for human studies must be met

Exclusion Criteria:

   - Patients with regional node involvement as their only site of disease beyond the
   primary tumor will not be eligible

   - Patients whose primary tumors arise in the intra-dural soft tissue (eg. brain and
   spinal cord) are not eligible

   - Patients who have received prior chemotherapy or radiation therapy are not eligible

   - Female patients of childbearing potential are not eligible unless a negative pregnancy
   test result has been obtained; lactating females are not eligible unless they have
   agreed not to breastfeed their infants for the duration of protocol therapy; sexually
   active patients of reproductive potential are not eligible unless they have agreed to
   use an effective contraceptive method for the duration of protocol therapy

   - Patients with known pre-existing diabetes mellitus will be excluded from study

   - Patients receiving chronic pharmacologic doses of corticosteroids are not eligible;
   for the purposes of eligibility, chronic exposure is defined as anticipated exposure
   of > 3 weeks, including the sum of both pre-enrollment and anticipated post-enrollment
   dosing; patients on acute corticosteroid therapy (=< 3 weeks of total planned
   exposure) must still meet the normal blood glucose requirement; patients receiving
   chronic inhaled corticosteroids or chronic physiologic replacement doses of
   corticosteroids are eligible

Ages Eligible for Study

N/A - 50 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christina Baggott
650-497-7659
Recruiting

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without ganitumab in treating patients with newly diagnosed Ewing sarcoma.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: Cyclophosphamide
  • Drug: Doxorubicin Hydrochloride
  • Drug: Etoposide
  • Radiation: External Beam Radiation Therapy
  • Biological: Ganitumab
  • Drug: Ifosfamide
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Radiation: Stereotactic Radiosurgery
  • Procedure: Therapeutic Surgical Procedure
  • Drug: Vincristine Sulfate

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed
   Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone
   or soft tissue and with metastatic disease involving lung, bone, bone marrow, or other
   metastatic site

   - For the purpose of this study metastatic disease is defined as one or more of the
   following:

      - Lesions which are discontinuous from the primary tumor, are not regional lymph
      nodes, and do not share a bone or body cavity with the primary tumor; skip
      lesions in the same bone as the primary tumor do not constitute metastatic
      disease; skip lesions in an adjacent bone are considered bone metastases; if
      there is any doubt whether lesions are metastatic, a biopsy of those lesions
      should be performed

      - Contralateral pleural effusion and/or contralateral pleural nodules

      - Distant lymph node involvement

      - Patients with pulmonary nodules are considered to have metastatic disease if the
      patient has:

         - Solitary nodule >= 0.5 cm or multiple nodules of >= 0.3 cm unless lesion is
         biopsied and negative for tumor

         - Patients with solitary nodule < 0.5 cm or multiple nodules < 0.3 cm are not
         considered to have lung metastasis unless biopsy documents tumor

      - Bone marrow metastatic disease is based on morphologic evidence of Ewing sarcoma
      based on hematoxylin and eosin (H&E) stains; in the absence of morphologic
      evidence of marrow involvement on H&E, patients with bone marrow involvement
      detected ONLY by flow cytometry, reverse-transcriptase (RT)-polymerase chain
      reaction (PCR), fluorescence in situ hybridization (FISH), or
      immunohistochemistry will NOT be considered to have clinical bone marrow
      involvement for the purposes of this study

         - This study requires bilateral bone marrow biopsies at study entry; the
         suggested approach for patients with large pelvic tumors in which a
         posterior iliac crest bone marrow biopsy would track through the tumor is to
         instead undergo 2 marrow biopsies on the contralateral side (either 2
         posterior biopsies or one posterior and one anterior biopsy)

      - Bone metastasis: This study utilizes whole body FDG-PET scans to screen patients
      for bone metastases; areas suspicious for bone metastasis based on FDG-PET scans
      require confirmatory anatomic imaging with either MRI or computed tomography (CT)
      (whole body FDG-PET/CT or FDG-PET/magnetic resonance [MR] scan acceptable); whole
      body technetium bone scans may be performed at the discretion of the investigator
      and are not required; for patients without other sites of metastatic disease
      whose sole metastatic site to qualify for study entry is a single area suspicious
      for bone metastasis identified by FDG-PET, confirmatory biopsy or anatomic
      imaging evidence of an associated soft tissue mass at that site is required for
      study entry

   - Patients must have adequate tumor tissue to meet the minimum requirement for
   submission

   - Enrolling institutions are reminded that submission of pre-treatment serum, tumor
   tissue and whole blood is required

   - Patients should only have had a biopsy of the primary tumor without an attempt at
   complete or partial resection; patients will still be eligible if excision was
   attempted or accomplished as long as adequate anatomic imaging (MRI for most primary
   tumor sites) was obtained prior to surgery

   - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
   mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

      - Age < 6 months: Maximum serum creatinine (mg/dL): 0.4 for males and females

      - Age 6 months to < 1 year: Maximum serum creatinine (mg/dL): 0.5 for males and
      females

      - Age 1 to < 2 years: Maximum serum creatinine (mg/dL): 0.6 for males and females

      - Age 2 to < 6 years: Maximum serum creatinine (mg/dL): 0.8 for males and females

      - Age 6 to < 10 years: Maximum serum creatinine (mg/dL): 1 for males and females

      - Age 10 to < 13 years: Maximum serum creatinine (mg/dL): 1.2 for males and females

      - Age 13 to < 16 years: Maximum serum creatinine (mg/dL): 1.5 for males and 1.4 for
      females

      - Age >= 16 years: Maximum serum creatinine (mg/dL): 1.7 for males and 1.4 for
      females

   - Total bilirubin =< 1.5 x upper limit of normal (ULN) for age, and

   - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 3 x
   upper limit of normal (ULN) for age (except for patients with liver metastasis who may
   enroll if ALT < 5 times ULN for age)

   - Shortening fraction of >= 27% or

   - Ejection fraction of >= 50%

   - Patients must have a normal blood sugar level for age to participate; if an initial
   random draw (ie. non-fasting) blood glucose value is out of range, it is acceptable to
   repeat this test as a fasting draw

   - All patients and/or their parents or legal guardians must sign a written informed
   consent

   - All institutional, Food and Drug Administration (FDA), and National Cancer Institute
   (NCI) requirements for human studies must be met

Exclusion Criteria:

   - Patients with regional node involvement as their only site of disease beyond the
   primary tumor will not be eligible

   - Patients whose primary tumors arise in the intra-dural soft tissue (eg. brain and
   spinal cord) are not eligible

   - Patients who have received prior chemotherapy or radiation therapy are not eligible

   - Female patients of childbearing potential are not eligible unless a negative pregnancy
   test result has been obtained; lactating females are not eligible unless they have
   agreed not to breastfeed their infants for the duration of protocol therapy; sexually
   active patients of reproductive potential are not eligible unless they have agreed to
   use an effective contraceptive method for the duration of protocol therapy

   - Patients with known pre-existing diabetes mellitus will be excluded from study

   - Patients receiving chronic pharmacologic doses of corticosteroids are not eligible;
   for the purposes of eligibility, chronic exposure is defined as anticipated exposure
   of > 3 weeks, including the sum of both pre-enrollment and anticipated post-enrollment
   dosing; patients on acute corticosteroid therapy (=< 3 weeks of total planned
   exposure) must still meet the normal blood glucose requirement; patients receiving
   chronic inhaled corticosteroids or chronic physiologic replacement doses of
   corticosteroids are eligible

Ages Eligible for Study

N/A - 50 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christina Baggott
650-497-7659
Recruiting

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without ganitumab in treating patients with newly diagnosed Ewing sarcoma.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: Cyclophosphamide
  • Drug: Doxorubicin Hydrochloride
  • Drug: Etoposide
  • Radiation: External Beam Radiation Therapy
  • Biological: Ganitumab
  • Drug: Ifosfamide
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Radiation: Stereotactic Radiosurgery
  • Procedure: Therapeutic Surgical Procedure
  • Drug: Vincristine Sulfate

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed
   Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone
   or soft tissue and with metastatic disease involving lung, bone, bone marrow, or other
   metastatic site

   - For the purpose of this study metastatic disease is defined as one or more of the
   following:

      - Lesions which are discontinuous from the primary tumor, are not regional lymph
      nodes, and do not share a bone or body cavity with the primary tumor; skip
      lesions in the same bone as the primary tumor do not constitute metastatic
      disease; skip lesions in an adjacent bone are considered bone metastases; if
      there is any doubt whether lesions are metastatic, a biopsy of those lesions
      should be performed

      - Contralateral pleural effusion and/or contralateral pleural nodules

      - Distant lymph node involvement

      - Patients with pulmonary nodules are considered to have metastatic disease if the
      patient has:

         - Solitary nodule >= 0.5 cm or multiple nodules of >= 0.3 cm unless lesion is
         biopsied and negative for tumor

         - Patients with solitary nodule < 0.5 cm or multiple nodules < 0.3 cm are not
         considered to have lung metastasis unless biopsy documents tumor

      - Bone marrow metastatic disease is based on morphologic evidence of Ewing sarcoma
      based on hematoxylin and eosin (H&E) stains; in the absence of morphologic
      evidence of marrow involvement on H&E, patients with bone marrow involvement
      detected ONLY by flow cytometry, reverse-transcriptase (RT)-polymerase chain
      reaction (PCR), fluorescence in situ hybridization (FISH), or
      immunohistochemistry will NOT be considered to have clinical bone marrow
      involvement for the purposes of this study

         - This study requires bilateral bone marrow biopsies at study entry; the
         suggested approach for patients with large pelvic tumors in which a
         posterior iliac crest bone marrow biopsy would track through the tumor is to
         instead undergo 2 marrow biopsies on the contralateral side (either 2
         posterior biopsies or one posterior and one anterior biopsy)

      - Bone metastasis: This study utilizes whole body FDG-PET scans to screen patients
      for bone metastases; areas suspicious for bone metastasis based on FDG-PET scans
      require confirmatory anatomic imaging with either MRI or computed tomography (CT)
      (whole body FDG-PET/CT or FDG-PET/magnetic resonance [MR] scan acceptable); whole
      body technetium bone scans may be performed at the discretion of the investigator
      and are not required; for patients without other sites of metastatic disease
      whose sole metastatic site to qualify for study entry is a single area suspicious
      for bone metastasis identified by FDG-PET, confirmatory biopsy or anatomic
      imaging evidence of an associated soft tissue mass at that site is required for
      study entry

   - Patients must have adequate tumor tissue to meet the minimum requirement for
   submission

   - Enrolling institutions are reminded that submission of pre-treatment serum, tumor
   tissue and whole blood is required

   - Patients should only have had a biopsy of the primary tumor without an attempt at
   complete or partial resection; patients will still be eligible if excision was
   attempted or accomplished as long as adequate anatomic imaging (MRI for most primary
   tumor sites) was obtained prior to surgery

   - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
   mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

      - Age < 6 months: Maximum serum creatinine (mg/dL): 0.4 for males and females

      - Age 6 months to < 1 year: Maximum serum creatinine (mg/dL): 0.5 for males and
      females

      - Age 1 to < 2 years: Maximum serum creatinine (mg/dL): 0.6 for males and females

      - Age 2 to < 6 years: Maximum serum creatinine (mg/dL): 0.8 for males and females

      - Age 6 to < 10 years: Maximum serum creatinine (mg/dL): 1 for males and females

      - Age 10 to < 13 years: Maximum serum creatinine (mg/dL): 1.2 for males and females

      - Age 13 to < 16 years: Maximum serum creatinine (mg/dL): 1.5 for males and 1.4 for
      females

      - Age >= 16 years: Maximum serum creatinine (mg/dL): 1.7 for males and 1.4 for
      females

   - Total bilirubin =< 1.5 x upper limit of normal (ULN) for age, and

   - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 3 x
   upper limit of normal (ULN) for age (except for patients with liver metastasis who may
   enroll if ALT < 5 times ULN for age)

   - Shortening fraction of >= 27% or

   - Ejection fraction of >= 50%

   - Patients must have a normal blood sugar level for age to participate; if an initial
   random draw (ie. non-fasting) blood glucose value is out of range, it is acceptable to
   repeat this test as a fasting draw

   - All patients and/or their parents or legal guardians must sign a written informed
   consent

   - All institutional, Food and Drug Administration (FDA), and National Cancer Institute
   (NCI) requirements for human studies must be met

Exclusion Criteria:

   - Patients with regional node involvement as their only site of disease beyond the
   primary tumor will not be eligible

   - Patients whose primary tumors arise in the intra-dural soft tissue (eg. brain and
   spinal cord) are not eligible

   - Patients who have received prior chemotherapy or radiation therapy are not eligible

   - Female patients of childbearing potential are not eligible unless a negative pregnancy
   test result has been obtained; lactating females are not eligible unless they have
   agreed not to breastfeed their infants for the duration of protocol therapy; sexually
   active patients of reproductive potential are not eligible unless they have agreed to
   use an effective contraceptive method for the duration of protocol therapy

   - Patients with known pre-existing diabetes mellitus will be excluded from study

   - Patients receiving chronic pharmacologic doses of corticosteroids are not eligible;
   for the purposes of eligibility, chronic exposure is defined as anticipated exposure
   of > 3 weeks, including the sum of both pre-enrollment and anticipated post-enrollment
   dosing; patients on acute corticosteroid therapy (=< 3 weeks of total planned
   exposure) must still meet the normal blood glucose requirement; patients receiving
   chronic inhaled corticosteroids or chronic physiologic replacement doses of
   corticosteroids are eligible

Ages Eligible for Study

N/A - 50 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christina Baggott
650-497-7659
Recruiting

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without ganitumab in treating patients with newly diagnosed Ewing sarcoma.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: Cyclophosphamide
  • Drug: Doxorubicin Hydrochloride
  • Drug: Etoposide
  • Radiation: External Beam Radiation Therapy
  • Biological: Ganitumab
  • Drug: Ifosfamide
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Radiation: Stereotactic Radiosurgery
  • Procedure: Therapeutic Surgical Procedure
  • Drug: Vincristine Sulfate

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed
   Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone
   or soft tissue and with metastatic disease involving lung, bone, bone marrow, or other
   metastatic site

   - For the purpose of this study metastatic disease is defined as one or more of the
   following:

      - Lesions which are discontinuous from the primary tumor, are not regional lymph
      nodes, and do not share a bone or body cavity with the primary tumor; skip
      lesions in the same bone as the primary tumor do not constitute metastatic
      disease; skip lesions in an adjacent bone are considered bone metastases; if
      there is any doubt whether lesions are metastatic, a biopsy of those lesions
      should be performed

      - Contralateral pleural effusion and/or contralateral pleural nodules

      - Distant lymph node involvement

      - Patients with pulmonary nodules are considered to have metastatic disease if the
      patient has:

         - Solitary nodule >= 0.5 cm or multiple nodules of >= 0.3 cm unless lesion is
         biopsied and negative for tumor

         - Patients with solitary nodule < 0.5 cm or multiple nodules < 0.3 cm are not
         considered to have lung metastasis unless biopsy documents tumor

      - Bone marrow metastatic disease is based on morphologic evidence of Ewing sarcoma
      based on hematoxylin and eosin (H&E) stains; in the absence of morphologic
      evidence of marrow involvement on H&E, patients with bone marrow involvement
      detected ONLY by flow cytometry, reverse-transcriptase (RT)-polymerase chain
      reaction (PCR), fluorescence in situ hybridization (FISH), or
      immunohistochemistry will NOT be considered to have clinical bone marrow
      involvement for the purposes of this study

         - This study requires bilateral bone marrow biopsies at study entry; the
         suggested approach for patients with large pelvic tumors in which a
         posterior iliac crest bone marrow biopsy would track through the tumor is to
         instead undergo 2 marrow biopsies on the contralateral side (either 2
         posterior biopsies or one posterior and one anterior biopsy)

      - Bone metastasis: This study utilizes whole body FDG-PET scans to screen patients
      for bone metastases; areas suspicious for bone metastasis based on FDG-PET scans
      require confirmatory anatomic imaging with either MRI or computed tomography (CT)
      (whole body FDG-PET/CT or FDG-PET/magnetic resonance [MR] scan acceptable); whole
      body technetium bone scans may be performed at the discretion of the investigator
      and are not required; for patients without other sites of metastatic disease
      whose sole metastatic site to qualify for study entry is a single area suspicious
      for bone metastasis identified by FDG-PET, confirmatory biopsy or anatomic
      imaging evidence of an associated soft tissue mass at that site is required for
      study entry

   - Patients must have adequate tumor tissue to meet the minimum requirement for
   submission

   - Enrolling institutions are reminded that submission of pre-treatment serum, tumor
   tissue and whole blood is required

   - Patients should only have had a biopsy of the primary tumor without an attempt at
   complete or partial resection; patients will still be eligible if excision was
   attempted or accomplished as long as adequate anatomic imaging (MRI for most primary
   tumor sites) was obtained prior to surgery

   - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
   mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

      - Age < 6 months: Maximum serum creatinine (mg/dL): 0.4 for males and females

      - Age 6 months to < 1 year: Maximum serum creatinine (mg/dL): 0.5 for males and
      females

      - Age 1 to < 2 years: Maximum serum creatinine (mg/dL): 0.6 for males and females

      - Age 2 to < 6 years: Maximum serum creatinine (mg/dL): 0.8 for males and females

      - Age 6 to < 10 years: Maximum serum creatinine (mg/dL): 1 for males and females

      - Age 10 to < 13 years: Maximum serum creatinine (mg/dL): 1.2 for males and females

      - Age 13 to < 16 years: Maximum serum creatinine (mg/dL): 1.5 for males and 1.4 for
      females

      - Age >= 16 years: Maximum serum creatinine (mg/dL): 1.7 for males and 1.4 for
      females

   - Total bilirubin =< 1.5 x upper limit of normal (ULN) for age, and

   - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 3 x
   upper limit of normal (ULN) for age (except for patients with liver metastasis who may
   enroll if ALT < 5 times ULN for age)

   - Shortening fraction of >= 27% or

   - Ejection fraction of >= 50%

   - Patients must have a normal blood sugar level for age to participate; if an initial
   random draw (ie. non-fasting) blood glucose value is out of range, it is acceptable to
   repeat this test as a fasting draw

   - All patients and/or their parents or legal guardians must sign a written informed
   consent

   - All institutional, Food and Drug Administration (FDA), and National Cancer Institute
   (NCI) requirements for human studies must be met

Exclusion Criteria:

   - Patients with regional node involvement as their only site of disease beyond the
   primary tumor will not be eligible

   - Patients whose primary tumors arise in the intra-dural soft tissue (eg. brain and
   spinal cord) are not eligible

   - Patients who have received prior chemotherapy or radiation therapy are not eligible

   - Female patients of childbearing potential are not eligible unless a negative pregnancy
   test result has been obtained; lactating females are not eligible unless they have
   agreed not to breastfeed their infants for the duration of protocol therapy; sexually
   active patients of reproductive potential are not eligible unless they have agreed to
   use an effective contraceptive method for the duration of protocol therapy

   - Patients with known pre-existing diabetes mellitus will be excluded from study

   - Patients receiving chronic pharmacologic doses of corticosteroids are not eligible;
   for the purposes of eligibility, chronic exposure is defined as anticipated exposure
   of > 3 weeks, including the sum of both pre-enrollment and anticipated post-enrollment
   dosing; patients on acute corticosteroid therapy (=< 3 weeks of total planned
   exposure) must still meet the normal blood glucose requirement; patients receiving
   chronic inhaled corticosteroids or chronic physiologic replacement doses of
   corticosteroids are eligible

Ages Eligible for Study

N/A - 50 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christina Baggott
650-497-7659
Recruiting

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without ganitumab in treating patients with newly diagnosed Ewing sarcoma.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: Cyclophosphamide
  • Drug: Doxorubicin Hydrochloride
  • Drug: Etoposide
  • Radiation: External Beam Radiation Therapy
  • Biological: Ganitumab
  • Drug: Ifosfamide
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Radiation: Stereotactic Radiosurgery
  • Procedure: Therapeutic Surgical Procedure
  • Drug: Vincristine Sulfate

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed
   Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone
   or soft tissue and with metastatic disease involving lung, bone, bone marrow, or other
   metastatic site

   - For the purpose of this study metastatic disease is defined as one or more of the
   following:

      - Lesions which are discontinuous from the primary tumor, are not regional lymph
      nodes, and do not share a bone or body cavity with the primary tumor; skip
      lesions in the same bone as the primary tumor do not constitute metastatic
      disease; skip lesions in an adjacent bone are considered bone metastases; if
      there is any doubt whether lesions are metastatic, a biopsy of those lesions
      should be performed

      - Contralateral pleural effusion and/or contralateral pleural nodules

      - Distant lymph node involvement

      - Patients with pulmonary nodules are considered to have metastatic disease if the
      patient has:

         - Solitary nodule >= 0.5 cm or multiple nodules of >= 0.3 cm unless lesion is
         biopsied and negative for tumor

         - Patients with solitary nodule < 0.5 cm or multiple nodules < 0.3 cm are not
         considered to have lung metastasis unless biopsy documents tumor

      - Bone marrow metastatic disease is based on morphologic evidence of Ewing sarcoma
      based on hematoxylin and eosin (H&E) stains; in the absence of morphologic
      evidence of marrow involvement on H&E, patients with bone marrow involvement
      detected ONLY by flow cytometry, reverse-transcriptase (RT)-polymerase chain
      reaction (PCR), fluorescence in situ hybridization (FISH), or
      immunohistochemistry will NOT be considered to have clinical bone marrow
      involvement for the purposes of this study

         - This study requires bilateral bone marrow biopsies at study entry; the
         suggested approach for patients with large pelvic tumors in which a
         posterior iliac crest bone marrow biopsy would track through the tumor is to
         instead undergo 2 marrow biopsies on the contralateral side (either 2
         posterior biopsies or one posterior and one anterior biopsy)

      - Bone metastasis: This study utilizes whole body FDG-PET scans to screen patients
      for bone metastases; areas suspicious for bone metastasis based on FDG-PET scans
      require confirmatory anatomic imaging with either MRI or computed tomography (CT)
      (whole body FDG-PET/CT or FDG-PET/magnetic resonance [MR] scan acceptable); whole
      body technetium bone scans may be performed at the discretion of the investigator
      and are not required; for patients without other sites of metastatic disease
      whose sole metastatic site to qualify for study entry is a single area suspicious
      for bone metastasis identified by FDG-PET, confirmatory biopsy or anatomic
      imaging evidence of an associated soft tissue mass at that site is required for
      study entry

   - Patients must have adequate tumor tissue to meet the minimum requirement for
   submission

   - Enrolling institutions are reminded that submission of pre-treatment serum, tumor
   tissue and whole blood is required

   - Patients should only have had a biopsy of the primary tumor without an attempt at
   complete or partial resection; patients will still be eligible if excision was
   attempted or accomplished as long as adequate anatomic imaging (MRI for most primary
   tumor sites) was obtained prior to surgery

   - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
   mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

      - Age < 6 months: Maximum serum creatinine (mg/dL): 0.4 for males and females

      - Age 6 months to < 1 year: Maximum serum creatinine (mg/dL): 0.5 for males and
      females

      - Age 1 to < 2 years: Maximum serum creatinine (mg/dL): 0.6 for males and females

      - Age 2 to < 6 years: Maximum serum creatinine (mg/dL): 0.8 for males and females

      - Age 6 to < 10 years: Maximum serum creatinine (mg/dL): 1 for males and females

      - Age 10 to < 13 years: Maximum serum creatinine (mg/dL): 1.2 for males and females

      - Age 13 to < 16 years: Maximum serum creatinine (mg/dL): 1.5 for males and 1.4 for
      females

      - Age >= 16 years: Maximum serum creatinine (mg/dL): 1.7 for males and 1.4 for
      females

   - Total bilirubin =< 1.5 x upper limit of normal (ULN) for age, and

   - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 3 x
   upper limit of normal (ULN) for age (except for patients with liver metastasis who may
   enroll if ALT < 5 times ULN for age)

   - Shortening fraction of >= 27% or

   - Ejection fraction of >= 50%

   - Patients must have a normal blood sugar level for age to participate; if an initial
   random draw (ie. non-fasting) blood glucose value is out of range, it is acceptable to
   repeat this test as a fasting draw

   - All patients and/or their parents or legal guardians must sign a written informed
   consent

   - All institutional, Food and Drug Administration (FDA), and National Cancer Institute
   (NCI) requirements for human studies must be met

Exclusion Criteria:

   - Patients with regional node involvement as their only site of disease beyond the
   primary tumor will not be eligible

   - Patients whose primary tumors arise in the intra-dural soft tissue (eg. brain and
   spinal cord) are not eligible

   - Patients who have received prior chemotherapy or radiation therapy are not eligible

   - Female patients of childbearing potential are not eligible unless a negative pregnancy
   test result has been obtained; lactating females are not eligible unless they have
   agreed not to breastfeed their infants for the duration of protocol therapy; sexually
   active patients of reproductive potential are not eligible unless they have agreed to
   use an effective contraceptive method for the duration of protocol therapy

   - Patients with known pre-existing diabetes mellitus will be excluded from study

   - Patients receiving chronic pharmacologic doses of corticosteroids are not eligible;
   for the purposes of eligibility, chronic exposure is defined as anticipated exposure
   of > 3 weeks, including the sum of both pre-enrollment and anticipated post-enrollment
   dosing; patients on acute corticosteroid therapy (=< 3 weeks of total planned
   exposure) must still meet the normal blood glucose requirement; patients receiving
   chronic inhaled corticosteroids or chronic physiologic replacement doses of
   corticosteroids are eligible

Ages Eligible for Study

N/A - 50 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christina Baggott
650-497-7659
Recruiting

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without ganitumab in treating patients with newly diagnosed Ewing sarcoma.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: Cyclophosphamide
  • Drug: Doxorubicin Hydrochloride
  • Drug: Etoposide
  • Radiation: External Beam Radiation Therapy
  • Biological: Ganitumab
  • Drug: Ifosfamide
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Radiation: Stereotactic Radiosurgery
  • Procedure: Therapeutic Surgical Procedure
  • Drug: Vincristine Sulfate

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed
   Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone
   or soft tissue and with metastatic disease involving lung, bone, bone marrow, or other
   metastatic site

   - For the purpose of this study metastatic disease is defined as one or more of the
   following:

      - Lesions which are discontinuous from the primary tumor, are not regional lymph
      nodes, and do not share a bone or body cavity with the primary tumor; skip
      lesions in the same bone as the primary tumor do not constitute metastatic
      disease; skip lesions in an adjacent bone are considered bone metastases; if
      there is any doubt whether lesions are metastatic, a biopsy of those lesions
      should be performed

      - Contralateral pleural effusion and/or contralateral pleural nodules

      - Distant lymph node involvement

      - Patients with pulmonary nodules are considered to have metastatic disease if the
      patient has:

         - Solitary nodule >= 0.5 cm or multiple nodules of >= 0.3 cm unless lesion is
         biopsied and negative for tumor

         - Patients with solitary nodule < 0.5 cm or multiple nodules < 0.3 cm are not
         considered to have lung metastasis unless biopsy documents tumor

      - Bone marrow metastatic disease is based on morphologic evidence of Ewing sarcoma
      based on hematoxylin and eosin (H&E) stains; in the absence of morphologic
      evidence of marrow involvement on H&E, patients with bone marrow involvement
      detected ONLY by flow cytometry, reverse-transcriptase (RT)-polymerase chain
      reaction (PCR), fluorescence in situ hybridization (FISH), or
      immunohistochemistry will NOT be considered to have clinical bone marrow
      involvement for the purposes of this study

         - This study requires bilateral bone marrow biopsies at study entry; the
         suggested approach for patients with large pelvic tumors in which a
         posterior iliac crest bone marrow biopsy would track through the tumor is to
         instead undergo 2 marrow biopsies on the contralateral side (either 2
         posterior biopsies or one posterior and one anterior biopsy)

      - Bone metastasis: This study utilizes whole body FDG-PET scans to screen patients
      for bone metastases; areas suspicious for bone metastasis based on FDG-PET scans
      require confirmatory anatomic imaging with either MRI or computed tomography (CT)
      (whole body FDG-PET/CT or FDG-PET/magnetic resonance [MR] scan acceptable); whole
      body technetium bone scans may be performed at the discretion of the investigator
      and are not required; for patients without other sites of metastatic disease
      whose sole metastatic site to qualify for study entry is a single area suspicious
      for bone metastasis identified by FDG-PET, confirmatory biopsy or anatomic
      imaging evidence of an associated soft tissue mass at that site is required for
      study entry

   - Patients must have adequate tumor tissue to meet the minimum requirement for
   submission

   - Enrolling institutions are reminded that submission of pre-treatment serum, tumor
   tissue and whole blood is required

   - Patients should only have had a biopsy of the primary tumor without an attempt at
   complete or partial resection; patients will still be eligible if excision was
   attempted or accomplished as long as adequate anatomic imaging (MRI for most primary
   tumor sites) was obtained prior to surgery

   - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
   mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

      - Age < 6 months: Maximum serum creatinine (mg/dL): 0.4 for males and females

      - Age 6 months to < 1 year: Maximum serum creatinine (mg/dL): 0.5 for males and
      females

      - Age 1 to < 2 years: Maximum serum creatinine (mg/dL): 0.6 for males and females

      - Age 2 to < 6 years: Maximum serum creatinine (mg/dL): 0.8 for males and females

      - Age 6 to < 10 years: Maximum serum creatinine (mg/dL): 1 for males and females

      - Age 10 to < 13 years: Maximum serum creatinine (mg/dL): 1.2 for males and females

      - Age 13 to < 16 years: Maximum serum creatinine (mg/dL): 1.5 for males and 1.4 for
      females

      - Age >= 16 years: Maximum serum creatinine (mg/dL): 1.7 for males and 1.4 for
      females

   - Total bilirubin =< 1.5 x upper limit of normal (ULN) for age, and

   - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 3 x
   upper limit of normal (ULN) for age (except for patients with liver metastasis who may
   enroll if ALT < 5 times ULN for age)

   - Shortening fraction of >= 27% or

   - Ejection fraction of >= 50%

   - Patients must have a normal blood sugar level for age to participate; if an initial
   random draw (ie. non-fasting) blood glucose value is out of range, it is acceptable to
   repeat this test as a fasting draw

   - All patients and/or their parents or legal guardians must sign a written informed
   consent

   - All institutional, Food and Drug Administration (FDA), and National Cancer Institute
   (NCI) requirements for human studies must be met

Exclusion Criteria:

   - Patients with regional node involvement as their only site of disease beyond the
   primary tumor will not be eligible

   - Patients whose primary tumors arise in the intra-dural soft tissue (eg. brain and
   spinal cord) are not eligible

   - Patients who have received prior chemotherapy or radiation therapy are not eligible

   - Female patients of childbearing potential are not eligible unless a negative pregnancy
   test result has been obtained; lactating females are not eligible unless they have
   agreed not to breastfeed their infants for the duration of protocol therapy; sexually
   active patients of reproductive potential are not eligible unless they have agreed to
   use an effective contraceptive method for the duration of protocol therapy

   - Patients with known pre-existing diabetes mellitus will be excluded from study

   - Patients receiving chronic pharmacologic doses of corticosteroids are not eligible;
   for the purposes of eligibility, chronic exposure is defined as anticipated exposure
   of > 3 weeks, including the sum of both pre-enrollment and anticipated post-enrollment
   dosing; patients on acute corticosteroid therapy (=< 3 weeks of total planned
   exposure) must still meet the normal blood glucose requirement; patients receiving
   chronic inhaled corticosteroids or chronic physiologic replacement doses of
   corticosteroids are eligible

Ages Eligible for Study

N/A - 50 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christina Baggott
650-497-7659
Recruiting

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without ganitumab in treating patients with newly diagnosed Ewing sarcoma.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: Cyclophosphamide
  • Drug: Doxorubicin Hydrochloride
  • Drug: Etoposide
  • Radiation: External Beam Radiation Therapy
  • Biological: Ganitumab
  • Drug: Ifosfamide
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Radiation: Stereotactic Radiosurgery
  • Procedure: Therapeutic Surgical Procedure
  • Drug: Vincristine Sulfate

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed
   Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone
   or soft tissue and with metastatic disease involving lung, bone, bone marrow, or other
   metastatic site

   - For the purpose of this study metastatic disease is defined as one or more of the
   following:

      - Lesions which are discontinuous from the primary tumor, are not regional lymph
      nodes, and do not share a bone or body cavity with the primary tumor; skip
      lesions in the same bone as the primary tumor do not constitute metastatic
      disease; skip lesions in an adjacent bone are considered bone metastases; if
      there is any doubt whether lesions are metastatic, a biopsy of those lesions
      should be performed

      - Contralateral pleural effusion and/or contralateral pleural nodules

      - Distant lymph node involvement

      - Patients with pulmonary nodules are considered to have metastatic disease if the
      patient has:

         - Solitary nodule >= 0.5 cm or multiple nodules of >= 0.3 cm unless lesion is
         biopsied and negative for tumor

         - Patients with solitary nodule < 0.5 cm or multiple nodules < 0.3 cm are not
         considered to have lung metastasis unless biopsy documents tumor

      - Bone marrow metastatic disease is based on morphologic evidence of Ewing sarcoma
      based on hematoxylin and eosin (H&E) stains; in the absence of morphologic
      evidence of marrow involvement on H&E, patients with bone marrow involvement
      detected ONLY by flow cytometry, reverse-transcriptase (RT)-polymerase chain
      reaction (PCR), fluorescence in situ hybridization (FISH), or
      immunohistochemistry will NOT be considered to have clinical bone marrow
      involvement for the purposes of this study

         - This study requires bilateral bone marrow biopsies at study entry; the
         suggested approach for patients with large pelvic tumors in which a
         posterior iliac crest bone marrow biopsy would track through the tumor is to
         instead undergo 2 marrow biopsies on the contralateral side (either 2
         posterior biopsies or one posterior and one anterior biopsy)

      - Bone metastasis: This study utilizes whole body FDG-PET scans to screen patients
      for bone metastases; areas suspicious for bone metastasis based on FDG-PET scans
      require confirmatory anatomic imaging with either MRI or computed tomography (CT)
      (whole body FDG-PET/CT or FDG-PET/magnetic resonance [MR] scan acceptable); whole
      body technetium bone scans may be performed at the discretion of the investigator
      and are not required; for patients without other sites of metastatic disease
      whose sole metastatic site to qualify for study entry is a single area suspicious
      for bone metastasis identified by FDG-PET, confirmatory biopsy or anatomic
      imaging evidence of an associated soft tissue mass at that site is required for
      study entry

   - Patients must have adequate tumor tissue to meet the minimum requirement for
   submission

   - Enrolling institutions are reminded that submission of pre-treatment serum, tumor
   tissue and whole blood is required

   - Patients should only have had a biopsy of the primary tumor without an attempt at
   complete or partial resection; patients will still be eligible if excision was
   attempted or accomplished as long as adequate anatomic imaging (MRI for most primary
   tumor sites) was obtained prior to surgery

   - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
   mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

      - Age < 6 months: Maximum serum creatinine (mg/dL): 0.4 for males and females

      - Age 6 months to < 1 year: Maximum serum creatinine (mg/dL): 0.5 for males and
      females

      - Age 1 to < 2 years: Maximum serum creatinine (mg/dL): 0.6 for males and females

      - Age 2 to < 6 years: Maximum serum creatinine (mg/dL): 0.8 for males and females

      - Age 6 to < 10 years: Maximum serum creatinine (mg/dL): 1 for males and females

      - Age 10 to < 13 years: Maximum serum creatinine (mg/dL): 1.2 for males and females

      - Age 13 to < 16 years: Maximum serum creatinine (mg/dL): 1.5 for males and 1.4 for
      females

      - Age >= 16 years: Maximum serum creatinine (mg/dL): 1.7 for males and 1.4 for
      females

   - Total bilirubin =< 1.5 x upper limit of normal (ULN) for age, and

   - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 3 x
   upper limit of normal (ULN) for age (except for patients with liver metastasis who may
   enroll if ALT < 5 times ULN for age)

   - Shortening fraction of >= 27% or

   - Ejection fraction of >= 50%

   - Patients must have a normal blood sugar level for age to participate; if an initial
   random draw (ie. non-fasting) blood glucose value is out of range, it is acceptable to
   repeat this test as a fasting draw

   - All patients and/or their parents or legal guardians must sign a written informed
   consent

   - All institutional, Food and Drug Administration (FDA), and National Cancer Institute
   (NCI) requirements for human studies must be met

Exclusion Criteria:

   - Patients with regional node involvement as their only site of disease beyond the
   primary tumor will not be eligible

   - Patients whose primary tumors arise in the intra-dural soft tissue (eg. brain and
   spinal cord) are not eligible

   - Patients who have received prior chemotherapy or radiation therapy are not eligible

   - Female patients of childbearing potential are not eligible unless a negative pregnancy
   test result has been obtained; lactating females are not eligible unless they have
   agreed not to breastfeed their infants for the duration of protocol therapy; sexually
   active patients of reproductive potential are not eligible unless they have agreed to
   use an effective contraceptive method for the duration of protocol therapy

   - Patients with known pre-existing diabetes mellitus will be excluded from study

   - Patients receiving chronic pharmacologic doses of corticosteroids are not eligible;
   for the purposes of eligibility, chronic exposure is defined as anticipated exposure
   of > 3 weeks, including the sum of both pre-enrollment and anticipated post-enrollment
   dosing; patients on acute corticosteroid therapy (=< 3 weeks of total planned
   exposure) must still meet the normal blood glucose requirement; patients receiving
   chronic inhaled corticosteroids or chronic physiologic replacement doses of
   corticosteroids are eligible

Ages Eligible for Study

N/A - 50 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christina Baggott
650-497-7659
Recruiting

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without ganitumab in treating patients with newly diagnosed Ewing sarcoma.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: Cyclophosphamide
  • Drug: Doxorubicin Hydrochloride
  • Drug: Etoposide
  • Radiation: External Beam Radiation Therapy
  • Biological: Ganitumab
  • Drug: Ifosfamide
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Radiation: Stereotactic Radiosurgery
  • Procedure: Therapeutic Surgical Procedure
  • Drug: Vincristine Sulfate

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed
   Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone
   or soft tissue and with metastatic disease involving lung, bone, bone marrow, or other
   metastatic site

   - For the purpose of this study metastatic disease is defined as one or more of the
   following:

      - Lesions which are discontinuous from the primary tumor, are not regional lymph
      nodes, and do not share a bone or body cavity with the primary tumor; skip
      lesions in the same bone as the primary tumor do not constitute metastatic
      disease; skip lesions in an adjacent bone are considered bone metastases; if
      there is any doubt whether lesions are metastatic, a biopsy of those lesions
      should be performed

      - Contralateral pleural effusion and/or contralateral pleural nodules

      - Distant lymph node involvement

      - Patients with pulmonary nodules are considered to have metastatic disease if the
      patient has:

         - Solitary nodule >= 0.5 cm or multiple nodules of >= 0.3 cm unless lesion is
         biopsied and negative for tumor

         - Patients with solitary nodule < 0.5 cm or multiple nodules < 0.3 cm are not
         considered to have lung metastasis unless biopsy documents tumor

      - Bone marrow metastatic disease is based on morphologic evidence of Ewing sarcoma
      based on hematoxylin and eosin (H&E) stains; in the absence of morphologic
      evidence of marrow involvement on H&E, patients with bone marrow involvement
      detected ONLY by flow cytometry, reverse-transcriptase (RT)-polymerase chain
      reaction (PCR), fluorescence in situ hybridization (FISH), or
      immunohistochemistry will NOT be considered to have clinical bone marrow
      involvement for the purposes of this study

         - This study requires bilateral bone marrow biopsies at study entry; the
         suggested approach for patients with large pelvic tumors in which a
         posterior iliac crest bone marrow biopsy would track through the tumor is to
         instead undergo 2 marrow biopsies on the contralateral side (either 2
         posterior biopsies or one posterior and one anterior biopsy)

      - Bone metastasis: This study utilizes whole body FDG-PET scans to screen patients
      for bone metastases; areas suspicious for bone metastasis based on FDG-PET scans
      require confirmatory anatomic imaging with either MRI or computed tomography (CT)
      (whole body FDG-PET/CT or FDG-PET/magnetic resonance [MR] scan acceptable); whole
      body technetium bone scans may be performed at the discretion of the investigator
      and are not required; for patients without other sites of metastatic disease
      whose sole metastatic site to qualify for study entry is a single area suspicious
      for bone metastasis identified by FDG-PET, confirmatory biopsy or anatomic
      imaging evidence of an associated soft tissue mass at that site is required for
      study entry

   - Patients must have adequate tumor tissue to meet the minimum requirement for
   submission

   - Enrolling institutions are reminded that submission of pre-treatment serum, tumor
   tissue and whole blood is required

   - Patients should only have had a biopsy of the primary tumor without an attempt at
   complete or partial resection; patients will still be eligible if excision was
   attempted or accomplished as long as adequate anatomic imaging (MRI for most primary
   tumor sites) was obtained prior to surgery

   - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
   mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

      - Age < 6 months: Maximum serum creatinine (mg/dL): 0.4 for males and females

      - Age 6 months to < 1 year: Maximum serum creatinine (mg/dL): 0.5 for males and
      females

      - Age 1 to < 2 years: Maximum serum creatinine (mg/dL): 0.6 for males and females

      - Age 2 to < 6 years: Maximum serum creatinine (mg/dL): 0.8 for males and females

      - Age 6 to < 10 years: Maximum serum creatinine (mg/dL): 1 for males and females

      - Age 10 to < 13 years: Maximum serum creatinine (mg/dL): 1.2 for males and females

      - Age 13 to < 16 years: Maximum serum creatinine (mg/dL): 1.5 for males and 1.4 for
      females

      - Age >= 16 years: Maximum serum creatinine (mg/dL): 1.7 for males and 1.4 for
      females

   - Total bilirubin =< 1.5 x upper limit of normal (ULN) for age, and

   - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 3 x
   upper limit of normal (ULN) for age (except for patients with liver metastasis who may
   enroll if ALT < 5 times ULN for age)

   - Shortening fraction of >= 27% or

   - Ejection fraction of >= 50%

   - Patients must have a normal blood sugar level for age to participate; if an initial
   random draw (ie. non-fasting) blood glucose value is out of range, it is acceptable to
   repeat this test as a fasting draw

   - All patients and/or their parents or legal guardians must sign a written informed
   consent

   - All institutional, Food and Drug Administration (FDA), and National Cancer Institute
   (NCI) requirements for human studies must be met

Exclusion Criteria:

   - Patients with regional node involvement as their only site of disease beyond the
   primary tumor will not be eligible

   - Patients whose primary tumors arise in the intra-dural soft tissue (eg. brain and
   spinal cord) are not eligible

   - Patients who have received prior chemotherapy or radiation therapy are not eligible

   - Female patients of childbearing potential are not eligible unless a negative pregnancy
   test result has been obtained; lactating females are not eligible unless they have
   agreed not to breastfeed their infants for the duration of protocol therapy; sexually
   active patients of reproductive potential are not eligible unless they have agreed to
   use an effective contraceptive method for the duration of protocol therapy

   - Patients with known pre-existing diabetes mellitus will be excluded from study

   - Patients receiving chronic pharmacologic doses of corticosteroids are not eligible;
   for the purposes of eligibility, chronic exposure is defined as anticipated exposure
   of > 3 weeks, including the sum of both pre-enrollment and anticipated post-enrollment
   dosing; patients on acute corticosteroid therapy (=< 3 weeks of total planned
   exposure) must still meet the normal blood glucose requirement; patients receiving
   chronic inhaled corticosteroids or chronic physiologic replacement doses of
   corticosteroids are eligible

Ages Eligible for Study

N/A - 50 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christina Baggott
650-497-7659
Recruiting

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without ganitumab in treating patients with newly diagnosed Ewing sarcoma.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: Cyclophosphamide
  • Drug: Doxorubicin Hydrochloride
  • Drug: Etoposide
  • Radiation: External Beam Radiation Therapy
  • Biological: Ganitumab
  • Drug: Ifosfamide
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Radiation: Stereotactic Radiosurgery
  • Procedure: Therapeutic Surgical Procedure
  • Drug: Vincristine Sulfate

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed
   Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone
   or soft tissue and with metastatic disease involving lung, bone, bone marrow, or other
   metastatic site

   - For the purpose of this study metastatic disease is defined as one or more of the
   following:

      - Lesions which are discontinuous from the primary tumor, are not regional lymph
      nodes, and do not share a bone or body cavity with the primary tumor; skip
      lesions in the same bone as the primary tumor do not constitute metastatic
      disease; skip lesions in an adjacent bone are considered bone metastases; if
      there is any doubt whether lesions are metastatic, a biopsy of those lesions
      should be performed

      - Contralateral pleural effusion and/or contralateral pleural nodules

      - Distant lymph node involvement

      - Patients with pulmonary nodules are considered to have metastatic disease if the
      patient has:

         - Solitary nodule >= 0.5 cm or multiple nodules of >= 0.3 cm unless lesion is
         biopsied and negative for tumor

         - Patients with solitary nodule < 0.5 cm or multiple nodules < 0.3 cm are not
         considered to have lung metastasis unless biopsy documents tumor

      - Bone marrow metastatic disease is based on morphologic evidence of Ewing sarcoma
      based on hematoxylin and eosin (H&E) stains; in the absence of morphologic
      evidence of marrow involvement on H&E, patients with bone marrow involvement
      detected ONLY by flow cytometry, reverse-transcriptase (RT)-polymerase chain
      reaction (PCR), fluorescence in situ hybridization (FISH), or
      immunohistochemistry will NOT be considered to have clinical bone marrow
      involvement for the purposes of this study

         - This study requires bilateral bone marrow biopsies at study entry; the
         suggested approach for patients with large pelvic tumors in which a
         posterior iliac crest bone marrow biopsy would track through the tumor is to
         instead undergo 2 marrow biopsies on the contralateral side (either 2
         posterior biopsies or one posterior and one anterior biopsy)

      - Bone metastasis: This study utilizes whole body FDG-PET scans to screen patients
      for bone metastases; areas suspicious for bone metastasis based on FDG-PET scans
      require confirmatory anatomic imaging with either MRI or computed tomography (CT)
      (whole body FDG-PET/CT or FDG-PET/magnetic resonance [MR] scan acceptable); whole
      body technetium bone scans may be performed at the discretion of the investigator
      and are not required; for patients without other sites of metastatic disease
      whose sole metastatic site to qualify for study entry is a single area suspicious
      for bone metastasis identified by FDG-PET, confirmatory biopsy or anatomic
      imaging evidence of an associated soft tissue mass at that site is required for
      study entry

   - Patients must have adequate tumor tissue to meet the minimum requirement for
   submission

   - Enrolling institutions are reminded that submission of pre-treatment serum, tumor
   tissue and whole blood is required

   - Patients should only have had a biopsy of the primary tumor without an attempt at
   complete or partial resection; patients will still be eligible if excision was
   attempted or accomplished as long as adequate anatomic imaging (MRI for most primary
   tumor sites) was obtained prior to surgery

   - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
   mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

      - Age < 6 months: Maximum serum creatinine (mg/dL): 0.4 for males and females

      - Age 6 months to < 1 year: Maximum serum creatinine (mg/dL): 0.5 for males and
      females

      - Age 1 to < 2 years: Maximum serum creatinine (mg/dL): 0.6 for males and females

      - Age 2 to < 6 years: Maximum serum creatinine (mg/dL): 0.8 for males and females

      - Age 6 to < 10 years: Maximum serum creatinine (mg/dL): 1 for males and females

      - Age 10 to < 13 years: Maximum serum creatinine (mg/dL): 1.2 for males and females

      - Age 13 to < 16 years: Maximum serum creatinine (mg/dL): 1.5 for males and 1.4 for
      females

      - Age >= 16 years: Maximum serum creatinine (mg/dL): 1.7 for males and 1.4 for
      females

   - Total bilirubin =< 1.5 x upper limit of normal (ULN) for age, and

   - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 3 x
   upper limit of normal (ULN) for age (except for patients with liver metastasis who may
   enroll if ALT < 5 times ULN for age)

   - Shortening fraction of >= 27% or

   - Ejection fraction of >= 50%

   - Patients must have a normal blood sugar level for age to participate; if an initial
   random draw (ie. non-fasting) blood glucose value is out of range, it is acceptable to
   repeat this test as a fasting draw

   - All patients and/or their parents or legal guardians must sign a written informed
   consent

   - All institutional, Food and Drug Administration (FDA), and National Cancer Institute
   (NCI) requirements for human studies must be met

Exclusion Criteria:

   - Patients with regional node involvement as their only site of disease beyond the
   primary tumor will not be eligible

   - Patients whose primary tumors arise in the intra-dural soft tissue (eg. brain and
   spinal cord) are not eligible

   - Patients who have received prior chemotherapy or radiation therapy are not eligible

   - Female patients of childbearing potential are not eligible unless a negative pregnancy
   test result has been obtained; lactating females are not eligible unless they have
   agreed not to breastfeed their infants for the duration of protocol therapy; sexually
   active patients of reproductive potential are not eligible unless they have agreed to
   use an effective contraceptive method for the duration of protocol therapy

   - Patients with known pre-existing diabetes mellitus will be excluded from study

   - Patients receiving chronic pharmacologic doses of corticosteroids are not eligible;
   for the purposes of eligibility, chronic exposure is defined as anticipated exposure
   of > 3 weeks, including the sum of both pre-enrollment and anticipated post-enrollment
   dosing; patients on acute corticosteroid therapy (=< 3 weeks of total planned
   exposure) must still meet the normal blood glucose requirement; patients receiving
   chronic inhaled corticosteroids or chronic physiologic replacement doses of
   corticosteroids are eligible

Ages Eligible for Study

N/A - 50 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christina Baggott
650-497-7659
Recruiting

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without ganitumab in treating patients with newly diagnosed Ewing sarcoma.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: Cyclophosphamide
  • Drug: Doxorubicin Hydrochloride
  • Drug: Etoposide
  • Radiation: External Beam Radiation Therapy
  • Biological: Ganitumab
  • Drug: Ifosfamide
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Radiation: Stereotactic Radiosurgery
  • Procedure: Therapeutic Surgical Procedure
  • Drug: Vincristine Sulfate

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed
   Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone
   or soft tissue and with metastatic disease involving lung, bone, bone marrow, or other
   metastatic site

   - For the purpose of this study metastatic disease is defined as one or more of the
   following:

      - Lesions which are discontinuous from the primary tumor, are not regional lymph
      nodes, and do not share a bone or body cavity with the primary tumor; skip
      lesions in the same bone as the primary tumor do not constitute metastatic
      disease; skip lesions in an adjacent bone are considered bone metastases; if
      there is any doubt whether lesions are metastatic, a biopsy of those lesions
      should be performed

      - Contralateral pleural effusion and/or contralateral pleural nodules

      - Distant lymph node involvement

      - Patients with pulmonary nodules are considered to have metastatic disease if the
      patient has:

         - Solitary nodule >= 0.5 cm or multiple nodules of >= 0.3 cm unless lesion is
         biopsied and negative for tumor

         - Patients with solitary nodule < 0.5 cm or multiple nodules < 0.3 cm are not
         considered to have lung metastasis unless biopsy documents tumor

      - Bone marrow metastatic disease is based on morphologic evidence of Ewing sarcoma
      based on hematoxylin and eosin (H&E) stains; in the absence of morphologic
      evidence of marrow involvement on H&E, patients with bone marrow involvement
      detected ONLY by flow cytometry, reverse-transcriptase (RT)-polymerase chain
      reaction (PCR), fluorescence in situ hybridization (FISH), or
      immunohistochemistry will NOT be considered to have clinical bone marrow
      involvement for the purposes of this study

         - This study requires bilateral bone marrow biopsies at study entry; the
         suggested approach for patients with large pelvic tumors in which a
         posterior iliac crest bone marrow biopsy would track through the tumor is to
         instead undergo 2 marrow biopsies on the contralateral side (either 2
         posterior biopsies or one posterior and one anterior biopsy)

      - Bone metastasis: This study utilizes whole body FDG-PET scans to screen patients
      for bone metastases; areas suspicious for bone metastasis based on FDG-PET scans
      require confirmatory anatomic imaging with either MRI or computed tomography (CT)
      (whole body FDG-PET/CT or FDG-PET/magnetic resonance [MR] scan acceptable); whole
      body technetium bone scans may be performed at the discretion of the investigator
      and are not required; for patients without other sites of metastatic disease
      whose sole metastatic site to qualify for study entry is a single area suspicious
      for bone metastasis identified by FDG-PET, confirmatory biopsy or anatomic
      imaging evidence of an associated soft tissue mass at that site is required for
      study entry

   - Patients must have adequate tumor tissue to meet the minimum requirement for
   submission

   - Enrolling institutions are reminded that submission of pre-treatment serum, tumor
   tissue and whole blood is required

   - Patients should only have had a biopsy of the primary tumor without an attempt at
   complete or partial resection; patients will still be eligible if excision was
   attempted or accomplished as long as adequate anatomic imaging (MRI for most primary
   tumor sites) was obtained prior to surgery

   - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
   mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

      - Age < 6 months: Maximum serum creatinine (mg/dL): 0.4 for males and females

      - Age 6 months to < 1 year: Maximum serum creatinine (mg/dL): 0.5 for males and
      females

      - Age 1 to < 2 years: Maximum serum creatinine (mg/dL): 0.6 for males and females

      - Age 2 to < 6 years: Maximum serum creatinine (mg/dL): 0.8 for males and females

      - Age 6 to < 10 years: Maximum serum creatinine (mg/dL): 1 for males and females

      - Age 10 to < 13 years: Maximum serum creatinine (mg/dL): 1.2 for males and females

      - Age 13 to < 16 years: Maximum serum creatinine (mg/dL): 1.5 for males and 1.4 for
      females

      - Age >= 16 years: Maximum serum creatinine (mg/dL): 1.7 for males and 1.4 for
      females

   - Total bilirubin =< 1.5 x upper limit of normal (ULN) for age, and

   - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 3 x
   upper limit of normal (ULN) for age (except for patients with liver metastasis who may
   enroll if ALT < 5 times ULN for age)

   - Shortening fraction of >= 27% or

   - Ejection fraction of >= 50%

   - Patients must have a normal blood sugar level for age to participate; if an initial
   random draw (ie. non-fasting) blood glucose value is out of range, it is acceptable to
   repeat this test as a fasting draw

   - All patients and/or their parents or legal guardians must sign a written informed
   consent

   - All institutional, Food and Drug Administration (FDA), and National Cancer Institute
   (NCI) requirements for human studies must be met

Exclusion Criteria:

   - Patients with regional node involvement as their only site of disease beyond the
   primary tumor will not be eligible

   - Patients whose primary tumors arise in the intra-dural soft tissue (eg. brain and
   spinal cord) are not eligible

   - Patients who have received prior chemotherapy or radiation therapy are not eligible

   - Female patients of childbearing potential are not eligible unless a negative pregnancy
   test result has been obtained; lactating females are not eligible unless they have
   agreed not to breastfeed their infants for the duration of protocol therapy; sexually
   active patients of reproductive potential are not eligible unless they have agreed to
   use an effective contraceptive method for the duration of protocol therapy

   - Patients with known pre-existing diabetes mellitus will be excluded from study

   - Patients receiving chronic pharmacologic doses of corticosteroids are not eligible;
   for the purposes of eligibility, chronic exposure is defined as anticipated exposure
   of > 3 weeks, including the sum of both pre-enrollment and anticipated post-enrollment
   dosing; patients on acute corticosteroid therapy (=< 3 weeks of total planned
   exposure) must still meet the normal blood glucose requirement; patients receiving
   chronic inhaled corticosteroids or chronic physiologic replacement doses of
   corticosteroids are eligible

Ages Eligible for Study

N/A - 50 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christina Baggott
650-497-7659
Recruiting

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without ganitumab in treating patients with newly diagnosed Ewing sarcoma.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: Cyclophosphamide
  • Drug: Doxorubicin Hydrochloride
  • Drug: Etoposide
  • Radiation: External Beam Radiation Therapy
  • Biological: Ganitumab
  • Drug: Ifosfamide
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Radiation: Stereotactic Radiosurgery
  • Procedure: Therapeutic Surgical Procedure
  • Drug: Vincristine Sulfate

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed
   Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone
   or soft tissue and with metastatic disease involving lung, bone, bone marrow, or other
   metastatic site

   - For the purpose of this study metastatic disease is defined as one or more of the
   following:

      - Lesions which are discontinuous from the primary tumor, are not regional lymph
      nodes, and do not share a bone or body cavity with the primary tumor; skip
      lesions in the same bone as the primary tumor do not constitute metastatic
      disease; skip lesions in an adjacent bone are considered bone metastases; if
      there is any doubt whether lesions are metastatic, a biopsy of those lesions
      should be performed

      - Contralateral pleural effusion and/or contralateral pleural nodules

      - Distant lymph node involvement

      - Patients with pulmonary nodules are considered to have metastatic disease if the
      patient has:

         - Solitary nodule >= 0.5 cm or multiple nodules of >= 0.3 cm unless lesion is
         biopsied and negative for tumor

         - Patients with solitary nodule < 0.5 cm or multiple nodules < 0.3 cm are not
         considered to have lung metastasis unless biopsy documents tumor

      - Bone marrow metastatic disease is based on morphologic evidence of Ewing sarcoma
      based on hematoxylin and eosin (H&E) stains; in the absence of morphologic
      evidence of marrow involvement on H&E, patients with bone marrow involvement
      detected ONLY by flow cytometry, reverse-transcriptase (RT)-polymerase chain
      reaction (PCR), fluorescence in situ hybridization (FISH), or
      immunohistochemistry will NOT be considered to have clinical bone marrow
      involvement for the purposes of this study

         - This study requires bilateral bone marrow biopsies at study entry; the
         suggested approach for patients with large pelvic tumors in which a
         posterior iliac crest bone marrow biopsy would track through the tumor is to
         instead undergo 2 marrow biopsies on the contralateral side (either 2
         posterior biopsies or one posterior and one anterior biopsy)

      - Bone metastasis: This study utilizes whole body FDG-PET scans to screen patients
      for bone metastases; areas suspicious for bone metastasis based on FDG-PET scans
      require confirmatory anatomic imaging with either MRI or computed tomography (CT)
      (whole body FDG-PET/CT or FDG-PET/magnetic resonance [MR] scan acceptable); whole
      body technetium bone scans may be performed at the discretion of the investigator
      and are not required; for patients without other sites of metastatic disease
      whose sole metastatic site to qualify for study entry is a single area suspicious
      for bone metastasis identified by FDG-PET, confirmatory biopsy or anatomic
      imaging evidence of an associated soft tissue mass at that site is required for
      study entry

   - Patients must have adequate tumor tissue to meet the minimum requirement for
   submission

   - Enrolling institutions are reminded that submission of pre-treatment serum, tumor
   tissue and whole blood is required

   - Patients should only have had a biopsy of the primary tumor without an attempt at
   complete or partial resection; patients will still be eligible if excision was
   attempted or accomplished as long as adequate anatomic imaging (MRI for most primary
   tumor sites) was obtained prior to surgery

   - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
   mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

      - Age < 6 months: Maximum serum creatinine (mg/dL): 0.4 for males and females

      - Age 6 months to < 1 year: Maximum serum creatinine (mg/dL): 0.5 for males and
      females

      - Age 1 to < 2 years: Maximum serum creatinine (mg/dL): 0.6 for males and females

      - Age 2 to < 6 years: Maximum serum creatinine (mg/dL): 0.8 for males and females

      - Age 6 to < 10 years: Maximum serum creatinine (mg/dL): 1 for males and females

      - Age 10 to < 13 years: Maximum serum creatinine (mg/dL): 1.2 for males and females

      - Age 13 to < 16 years: Maximum serum creatinine (mg/dL): 1.5 for males and 1.4 for
      females

      - Age >= 16 years: Maximum serum creatinine (mg/dL): 1.7 for males and 1.4 for
      females

   - Total bilirubin =< 1.5 x upper limit of normal (ULN) for age, and

   - Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 3 x
   upper limit of normal (ULN) for age (except for patients with liver metastasis who may
   enroll if ALT < 5 times ULN for age)

   - Shortening fraction of >= 27% or

   - Ejection fraction of >= 50%

   - Patients must have a normal blood sugar level for age to participate; if an initial
   random draw (ie. non-fasting) blood glucose value is out of range, it is acceptable to
   repeat this test as a fasting draw

   - All patients and/or their parents or legal guardians must sign a written informed
   consent

   - All institutional, Food and Drug Administration (FDA), and National Cancer Institute
   (NCI) requirements for human studies must be met

Exclusion Criteria:

   - Patients with regional node involvement as their only site of disease beyond the
   primary tumor will not be eligible

   - Patients whose primary tumors arise in the intra-dural soft tissue (eg. brain and
   spinal cord) are not eligible

   - Patients who have received prior chemotherapy or radiation therapy are not eligible

   - Female patients of childbearing potential are not eligible unless a negative pregnancy
   test result has been obtained; lactating females are not eligible unless they have
   agreed not to breastfeed their infants for the duration of protocol therapy; sexually
   active patients of reproductive potential are not eligible unless they have agreed to
   use an effective contraceptive method for the duration of protocol therapy

   - Patients with known pre-existing diabetes mellitus will be excluded from study

   - Patients receiving chronic pharmacologic doses of corticosteroids are not eligible;
   for the purposes of eligibility, chronic exposure is defined as anticipated exposure
   of > 3 weeks, including the sum of both pre-enrollment and anticipated post-enrollment
   dosing; patients on acute corticosteroid therapy (=< 3 weeks of total planned
   exposure) must still meet the normal blood glucose requirement; patients receiving
   chronic inhaled corticosteroids or chronic physiologic replacement doses of
   corticosteroids are eligible

Ages Eligible for Study

N/A - 50 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christina Baggott
650-497-7659
Recruiting